A Phase 3 Study Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms in Postmenopausal Women With an Intact Uterus

Trial Profile

A Phase 3 Study Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms in Postmenopausal Women With an Intact Uterus

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2017

At a glance

  • Drugs Estradiol/progesterone (Primary)
  • Indications Vasomotor symptoms
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms REPLENISH
  • Sponsors TherapeuticsMD
  • Most Recent Events

    • 05 Oct 2017 According to a TherapeuticsMD media release, detailed findings from the study will be presented at the annual meeting of the North American Menopause Society (NAMS) 2017.
    • 04 Apr 2017 Primary endpoint has been met. (Primary Efficacy Endpoints: Vasomotor Symptoms (VMS Substudy)) as per results presented at The 99th Annual Meeting of the Endocrine Society
    • 04 Apr 2017 Results of Vasomotor Symptoms (VMS) Sub-study presented at The 99th Annual Meeting of the Endocrine Society
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top